Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics, Pharmacodynamics and Safety of Ziltivekimab Versus Placebo in Chinese Participants With Chronic Kidney Disease and Systemic Inflammation

NCT05379829 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05379829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05379829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics, Pharmacodynamics and Safety of Ziltivekimab Versus Placebo in Chinese Participants With Chronic Kidney Disease and Systemic Inflammation
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
May 30, 2022
Completion date
September 2, 2024
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease and systemic inflammation